Supernus Pharmaceuticals Inc. (SUPN)
NASDAQ · Healthcare
Supernus Pharmaceuticals Inc. Operating Income 2010–2025
Supernus Pharmaceuticals Inc. annual/quarterly operating income history and growth rate from 2010 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Supernus Pharmaceuticals Inc. operating income for the quarter ending March 31, 2026 was -8.3 M, a 18.76% decrease year-over-year.
- Supernus Pharmaceuticals Inc. operating income for the twelve months ending March 31, 2026 was -66.7 M, a 197.48% decrease year-over-year.
- Supernus Pharmaceuticals Inc. annual operating income for 2025 was -62.3 M, a 176.27% decrease from 2024.
- Supernus Pharmaceuticals Inc. annual operating income for 2024 was 81.7 M, a 1649.93% decrease from 2023.
- Supernus Pharmaceuticals Inc. annual operating income for 2023 was -5.3 M, a 111.42% decrease from 2022.
- Supernus Pharmaceuticals Inc. annual operating income for 2022 was 46.1 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Supernus Pharmaceuticals Inc. Operating Income — FAQ
Supernus Pharmaceuticals Inc. (SUPN) operating income over the last 16 years — annual and quarterly figures with year-over-year growth and charts.
What is Supernus Pharmaceuticals Inc.'s operating income?
Supernus Pharmaceuticals Inc. (SUPN) reported operating income of -$62M for fiscal 2025.
Where can I see SUPN's operating income history?
The chart and table above show Supernus Pharmaceuticals Inc.'s operating income by year and by quarter, including the growth rate.